Renal Late Effects in Patients Treated for Cancer in Childhood: A Report From the Children's Oncology Group

被引:96
作者
Jones, Deborah P. [1 ]
Spunt, Sheri L.
Green, Daniel [2 ]
Springate, James E.
机构
[1] Univ Tennessee, Hlth Sci Ctr, Le Bonheur Childrens Med Ctr, Childrens Fdn Res Ctr, Memphis, TN 38103 USA
[2] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Prevent, Memphis, TN 38105 USA
关键词
chronic kidney disease; cisplatin; hypertension; ifosfamide; methotrexate; nephrectomy; proteinuria; radiotherapy; Wilms' tumor;
D O I
10.1002/pbc.21695
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Improvements in childhood cancer therapy have led to increasing numbers of long-term survivors. These survivors are at risk for a variety of late effects due to the disease itself, treatment exposures (surgery, chemotherapy, and radiotherapy), underlying medical problems, and health behaviors. The COG LTFU Guidelines are risk-based, exposure-related recommendations for the identification and management of late effects due to therapies utilized in the treatment of childhood cancer, and are designed for asymptomatic survivors presenting for routine medical follow-up 2 or more years after completion of cancer therapy. The COG Guidelines Task Force on Urinary Tract Complications conducted an extensive review of the medical literature via MEDLINE. Specific treatment exposures which were reviewed include nephrectomy, chemotherapy regimens known to be nephrotoxic (cisplatin, carboplatin, ifosfamide, and methotrexate), and renal irradiation. Literature sources were ranked according to the strength of evidence and are cited in the review. This review summarizes the literature that supported the recommendations for cancer survivors at risk for nephrotoxicity previously outlined in the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers (COG LTFU Guidelines). Pediatr Blood Cancer 2008;51:724-731. (c) 2008 Wiley-Liss, Inc.
引用
收藏
页码:724 / 731
页数:8
相关论文
共 61 条
[1]  
Ariceta G, 1997, MED PEDIATR ONCOL, V28, P35, DOI 10.1002/(SICI)1096-911X(199701)28:1<35::AID-MPO7>3.0.CO
[2]  
2-U
[3]  
Arndt C, 1999, MED PEDIATR ONCOL, V32, P93, DOI 10.1002/(SICI)1096-911X(199902)32:2<93::AID-MPO4>3.0.CO
[4]  
2-Y
[5]   Nephrotoxicity in survivors of Wilms' tumours in the North of England [J].
Bailey, S ;
Roberts, A ;
Brock, C ;
Price, L ;
Craft, AW ;
Kilkarni, R ;
Lee, REJ ;
Skillen, AW ;
Skinner, R .
BRITISH JOURNAL OF CANCER, 2002, 87 (10) :1092-1098
[6]   High-dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity [J].
Berrak, SG ;
Pearson, M ;
Berberoglu, S ;
Ilhan, IE ;
Jaffe, N .
PEDIATRIC BLOOD & CANCER, 2005, 44 (03) :215-219
[7]   End stage renal disease in patients with Wilms tumor: Results from the National Wilms Tumor Study Group and the United States Renal Data System [J].
Breslow, NE ;
Collins, AJ ;
Ritchey, ML ;
Grigoriev, YA ;
Peterson, SM ;
Green, DM .
JOURNAL OF UROLOGY, 2005, 174 (05) :1972-1975
[8]  
BREWER E, 2003, PEDIAT NEPHROLOGY, P1180
[9]   PARTIAL REVERSIBILITY OF CISPLATIN NEPHROTOXICITY IN CHILDREN [J].
BROCK, PR ;
KOLIOUSKAS, DE ;
BARRATT, TM ;
YEOMANS, E ;
PRITCHARD, J .
JOURNAL OF PEDIATRICS, 1991, 118 (04) :531-534
[10]   IFOSFAMIDE-INDUCED RENAL TUBULAR DYSFUNCTION AND RICKETS IN CHILDREN WITH WILMS-TUMOR [J].
BURK, CD ;
RESTAINO, I ;
KAPLAN, BS ;
MEADOWS, AT .
JOURNAL OF PEDIATRICS, 1990, 117 (02) :331-335